Search

Your search keyword '"Barlier, Catherine"' showing total 12 results
Start Over Author "Barlier, Catherine"
12 results on '"Barlier, Catherine"'

1. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein

Author

Maran-Gonzalez, Aurélie, Franchet, Camille, Duprez-Paumier, Raphaëlle, Antoine, Martine, Barlier, Catherine, Becette, Véronique, Berghian, Anca, Blanc-Fournier, Cécile, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Fleury, Clémence, Garbar, Christian, Ghnassia, Jean-Pierre, Haudebourg, Juliette, MacGrogan, Gaëtan, Mathieu, Marie-Christine, Michenet, Patrick, Penault-Llorca, Frédérique, Poulet, Bruno, Robin, Yves, Roger, Pascal, Russ, Elisabeth, Treilleux, Isabelle, Valent, Alexander, Verriele, Véronique, Vincent-Salomon, Anne, Arnould, Laurent, and Lacroix-Triki, Magali

Published
2019
Full Text
View/download PDF

4. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein

Author

Maran-Gonzalez, Aurélie, Franchet, Camille, Duprez-Paumier, Raphaelle, Antoine, Martine, Barlier, Catherine, Bécette, Véronique, Berghian, Anca, Blanc-Fournier, Cécile, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Fleury, Clémence, Garbar, Christian, Ghnassia, Jean-Pierre, Haudebourg, Juliette, MacGrogan, Gaëtan, Mathieu, Marie-Christine, Michenet, Patrick, Penault-Llorca, Frédérique, Poulet, Bruno, Robin, Yves, Roger, Pascal, Russ, Elisabeth, Treilleux, Isabelle, Valent, Alexander, Verriele, Véronique, Vincent-Salomon, Anne, Arnould, Laurent, Lacroix-Triki, Magali, Institut du Cancer de Montpellier (ICM), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Hôpital René HUGUENIN (Saint-Cloud), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Jean Godinot [Reims], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de Hautepierre [Strasbourg], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut de Pathologie et Génétique [Gosselies] (I.P.G.), Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509 (IRMAIC), Université de Reims Champagne-Ardenne (URCA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Validation et identification de nouvelles cibles en oncologie (VINCO), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Hospitalier Régional d'Orléans (CHRO), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Université de Montpellier (UM), Département d'anatomopathologie, biopathologie, Centre Léon Bérard [Lyon], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Institut Curie [Paris], Université Lumière - Lyon 2 - UFR de Sciences économiques et de gestion (UL2 UFR SEG), Université Lumière - Lyon 2 (UL2), Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Lille Nord de France (COMUE)-UNICANCER, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CRLCC Institut Claudius Regaud, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pathology Bratislava, NUT a RCH, Service d'Anatomie Pathologique Générale, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service d'anatomo-pathologie, Centre Jean Perrin, Pathology Department, CRLCC Paul Strauss, Laboratoire d'Anatomo-Pathologie, Hôpital Pasteur [Nice] (CHU), Université Bordeaux Segalen - Bordeaux 2-Institut Bergonié - CRLCC Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pathologie, CHU Orléans, CRLCC Jean Perrin, Calculateurs Parallèles (CALCPAR), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS)-INRIA Rennes, Institut National de Recherche en Informatique et en Automatique (Inria), Institut de cancérologie de l'Ouest - Paul Papin (ICO - Paul Papin), Department of Tumor Biology, Institut Curie, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11)

Subjects
Neoplasm, Residual, Tissue sample, Recommandations, [SDV]Life Sciences [q-bio], Biopsy, Prélèvement, Breast Neoplasms, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Guidelines, Medical Records, Réponse pathologique, Specimen Handling, Breast cancer, Biomarkers, Tumor, Humans, Néoadjuvant, Breast, Cancer du sein, Microscopy, Sentinel Lymph Node Biopsy, Prognosis, Neoadjuvant Therapy, Tumor Burden, Treatment Outcome, Chemotherapy, Adjuvant, Female, France, Lymph Nodes, Drug Screening Assays, Antitumor, Pathological response
Abstract

International audience; Neoadjuvant therapy is an increasing treatment option in the management of breast cancer. The tumor response to neoadjuvant therapy, especially the pathological complete response, is a validated endpoint frequently used in clinical trials. However, there is still a lack of standardization for the surgical specimen management in the neoadjuvant setting. This leads to heterogeneity in the specimen handling and might lead to significant bias for the prognostic assessment of patients or in clinical trials. The GEFPICS group, composed of expert breast cancer pathologists, herein presents guidelines for the management of breast and axillary specimen before treatment (management of biopsy, items of the pathological report) and after neoadjuvant therapy (specimen handling, histological assessment of response, items of the pathological report and response grading systems).

Published
2018
Full Text
View/download PDF

6. Identification of druggable targets in high-grade epithelial ovarian cancer (EOC) using next generation sequencing (NGS)–based molecular diagnostic

Author

Chen, Shuhui, Cavazza, Elisa, Barlier, Catherine, Filhine-Tresarrieu, Pierre, Gavoille, Céline, Harlé, Alexandre, Merlin, Jean-Louis, Merlin, Jean-Louis, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Centre de Recherche en Automatique de Nancy (CRAN), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
endocrine system diseases, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]
Abstract

published in Journal of Clinical Oncology, 34(7-Suppl), 2016.; International audience; Background: Despite the great histological and molecular heterogeneity, the clinical management of EOC remains univocal. Additionally to conventional histological prognostic markers and oncogenetic investigations, molecular diagnostic was performed using NGS to identify "druggable" targets that could provide access to targeted therapy in high-grade EOC. Methods: This study was performed in 53 patients (pts) (mean age 58.9, range 25-87) with histologically proven high-grade EOC, mostly serous carcinomas (N = 45), 44 were treated by surgery, 9 received neo-adjuvant chemotherapy. BRCA1/2 germline mutations were screened in 19 pts with familial cancer history justifying oncogenetic investigations. P53 and PTEN expression was assessed on formalin fixed paraffin-embedded using immunohistochemistry. Somatic mutations of KRAS and NRAS (exons 2, 3 and 4), BRAF (exon 15), PIK3CA (exons 5, 10 and 21) and MET (exons 14, 16, 17, 18 and 19) were screened using NGS on DNA extracts from frozen tumor specimens taken at diagnosis. Sequences were aligned with reference sequences and variant calling was processed. At X1000 depth, NGS sensitivity was 1%. Mapping, sorting and indexing were performed twice using AVA, BWA and SAMtools. VarScan2 was finally used for variant calling. Results: With a median follow-up of 38.2 months (range 1.4-93.3), 24 pts are alive, 14 pts disease-free and15 progressed within 6 months after platinum-based therapy. All pts screened for BRCA mutations had serous EOC, mutations were detected in 7/19 pts. P53 overexpression was detected in 60% and PTEN loss in 41% of the pts. One KRAS (exon 2), 2 NRAS mutations (exon 3), 6 PIK3CA mutations (exon 5, 10 and 21) and 5 MET mutations (exons 14 and 18) were detected. All clear-cell EOC were mutated (N = 4). No mutation was found in endometrioid EOC (N = 3). All MET and NRAS mutations were found in serous EOC (N = 7). Conclusions: In high-grade EOC, NGS has adequate sensitivity and specificity to detect genetic abnormalities and provide molecular rationale for targeted therapies, potentially offering new therapeutic opportunities to the pts.

Published
2016

7. Investigation of druggable molecular targets in high grade ovarian tumors using next generation sequencing (NGS)

Author

Chen, Shuhui, Cavazza, Elisa, Barlier, Catherine, Filhine-Tresarrieu, Pierre, Gavoille, Céline, Merlin, Jean-Louis, Harlé, Alexandre, Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université de Lorraine (UL), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, and Merlin, Jean-Louis

Subjects
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], ComputingMethodologies_GENERAL, ComputingMilieux_MISCELLANEOUS
Abstract

Présentation Poster; National audience

Published
2015

8. Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets

Author

Chen, Shuhui, primary, Cavazza, Elisa, additional, Barlier, Catherine, additional, Salleron, Julia, additional, Filhine-Tresarrieu, Pierre, additional, Gavoilles, Céline, additional, Merlin, Jean-Louis, additional, and Harlé, Alexandre, additional

Published
2016
Full Text
View/download PDF

10. Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.

Author

SHUHUI CHEN, CAVAZZA, ELISA, BARLIER, CATHERINE, SALLERON, JULIA, FILHINE-TRESARRIEU, PIERRE, GAVOILLE, CÉLINE, MERLIN, JEAN-LOUIS, and HARLÉ, ALEXANDRE

Subjects
RAS oncogenes, JAK-STAT pathway, OVARIAN cancer, BREAST cancer diagnosis, PHOSPHATIDYLINOSITOL 3-kinases
Abstract

Despite great histological and molecular heterogeneity, the clinical management of high-grade ovarian carcinomas remains unspecialized. As a major subgroup, high-grade serous ovarian carcinomas (HGSOCs) require novel therapies. In addition to utilizing conventional histological prognostic markers and performing oncogenetic investigations, the molecular diagnostic method of next generation sequencing (NGS) was performed to identify 'druggable' targets that could provide access to innovative therapy. The present study was performed in 45 HGSOC patients (mean age, 59.1 years; range, 25-87 years) with histologically proven HGSOC. Breast cancer 1/2 (BRCA1/2) germline mutations were screened in 17 patients with a familial or personal history of cancer, which was justified by oncogenetic investigations. Tumor protein 53 (P53) and phosphatase and tensin homolog (PTEN) expression were assessed in formalin-fixed paraffin-embedded tissues using immunohistochemistry. Somatic mutations of Kirsten rat sarcoma viral oncogene homolog, neuroblastoma RAS viral oncogene homolog (NRAS), B-Raf proto-oncogene, serine/threonine kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) and MET proto-oncogene, receptor tyrosine kinase (MET) were screened using NGS on DNA extracts from frozen tumor specimens obtained at diagnosis. With a median follow-up of 38 months (range, 6-93 months), 20 patients are alive, 10 patients are disease-free and 14 patients progressed within 6 months following platinum-based therapy. P53 overexpression was detected in 67% of patients and PTEN loss was detected in 38% of the patients. The overexpression of mutant P53 was found to be associated with a longer progression-free and overall survival. In total, 2 NRAS (exon 3), 3 PIK3CA (exon 5 and 10) and 5 MET mutations (exons 14 and 18) were detected. In HGSOCs, in addition to P53 and PTEN alterations, somatic genetic abnormalities can be detected using NGS and provide molecular rationale for targeted therapies, potentially offering novel therapeutic opportunities to patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

12. Foslip®-based photodynamic therapy as a means to improve wound healing.

Author

Garrier, Julie, Bezdetnaya, Lina, Barlier, Catherine, Gräfe, Susanna, Guillemin, François, and D’Hallewin, Marie-Ange

Subjects
PHOTOCHEMOTHERAPY, WOUND healing, COLLAGEN, CONNECTIVE tissue cells, ELASTIN, LABORATORY mice
Abstract

Summary: Background: Collagen matrices as substitution for connective tissue are known to promote wound healing. Photodynamic therapy has been anecdotally associated with improved wound healing and reduced scarring. The present study investigates the impact of collagen based scaffolding material, embedded with a liposomal formulation of meta-tetra (hydroxyphenyl) chlorin (mTHPC, Foslip®) and photodynamic therapy on wound healing in mice. Methods: After incision in the neck region, two different types of collagen material, previously incubated with Foslip® at different concentrations, were implanted followed by illumination at 652nm (10J/cm2, 100mW/cm2). Mice were imaged daily up to two weeks, whereafter excision was performed and pathological analysis. Results: Scab detachment was observed at day seven for controls whereas it occurred as early as three days for PDT at the lowest concentrations. In the latter conditions, final matrix remodelling could be observed as evidenced by elastin neosynthesis. Conclusions: Topical application of low dose Foslip® in a collagen matrix followed by illumination considerably accelerates wound healing. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results